Ocumension Therapeutics (HKG:1477) completed the enrollment of more than 140 patients for the second phase 3 trial of its OT-301 nitric oxide-donating prostaglandin analog, according to a Tuesday filing with the Hong Kong Exchange.
The drug is indicated for the lowering of intraocular pressure in open-angle glaucoma and ocular hypertension in patients, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.